EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Summary

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

Eligibility

Inclusion Criteria:

* Recurrent locally advanced or metastatic solid tumors
* Homologous recombination deficient mutations
* Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
* Measurable disease (RECIST 1.1 Criteria)
* Adequate organ and bone marrow function
* ECOG Performance Status 0 or 1
* Life expectancy \> 3 months

Exclusion Criteria:

* History or evidence of any clinically relevant gastrointestinal disease
* Radiation therapy within ≤2 weeks
* Significant cardiovascular disease
* Uncontrolled, active, symptomatic brain metastases

Conditions4

Interventions3

Locations1 site

Find trials near these locations

Related trials

• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) — Canadian Cancer Trials Group
• Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer — Santa Chiara Hospital
• Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer — Akeso
• Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd — Gustave Roussy, Cancer Campus, Grand Paris
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors — Gustave Roussy, Cancer Campus, Grand Paris
• Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer — GBG Forschungs GmbH
• Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor — Seoul National University Hospital
• Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) — German Cancer Research Center

Browse More Trials